Commentary

Video

Translating Metabolic Therapies Into Sarcoma

Author(s):

Brian A. Van Tine, MD, PhD

Brian A. Van Tine, MD, PhD, of Washington University of St. Louis and Siteman Cancer Center, discusses how to translate metabolic therapies into sarcoma management.

Brian A. Van Tine, MD, PhD, of Washington University of St. Louis and Siteman Cancer Center, discusses how to translate metabolic therapies into sarcoma management.

Related Videos
Premal Thaker, MD, MS
Matthew Powell, MD
R. Lor Randall, MD, FACS
Margaret E. Gatti-Mays, MD, MPH, FACP
Javier Martín Broto MD, PhD
Breelyn Wilky, director, Sarcoma Medical Oncology, The Cheryl Bennett and McNeilly Family Endowed Chair in Sarcoma Research, deputy associate director, Clinical Research, associate professor, medicine, medical oncology, the University of Colorado Medicine
R. Lor Randall, MD, FACS
Andrew Davis, MD
Ciara Kelly, MBBCh, BAO
Related Content
IMNN-01 Plus Perioperative Chemotherapy Maintains OS Benefit in Newly Diagnosed Advanced Ovarian Cancer
December 10th 2024

IMNN-001 Plus Perioperative Chemotherapy Maintains OS Benefit in Newly Diagnosed Advanced Ovarian Cancer

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

November Recap
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024

Explore the Latest Treatment Updates in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen V. Liu, MD
November 27th 2024

Explore the Latest Treatment Updates in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen V. Liu, MD

2rogan – stock.adobe.com
November 12th 2024

Elraglusib Earns FDA Rare Pediatric Disease Designation for Ewing Sarcoma

Pimicotinib in Tenosynovial Giant Cell Tumor | Image Credit: © 2rogan - stock.adobe.com
November 12th 2024

Pimicotinib Meets ORR End Point in Tenosynovial Giant Cell Tumor